Pliant Therapeutics Inc (PLRX)
11.93
+0.05
(+0.42%)
USD |
NASDAQ |
Apr 26, 10:38
Pliant Therapeutics Cash from Operations (TTM): -116.36M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -116.36M |
September 30, 2023 | -122.50M |
June 30, 2023 | -104.77M |
March 31, 2023 | -104.41M |
December 31, 2022 | -94.63M |
September 30, 2022 | -83.26M |
June 30, 2022 | -87.27M |
March 31, 2022 | -82.28M |
December 31, 2021 | -75.44M |
Date | Value |
---|---|
September 30, 2021 | -72.06M |
June 30, 2021 | -65.34M |
March 31, 2021 | -38.17M |
December 31, 2020 | -37.27M |
September 30, 2020 | 15.96M |
June 30, 2020 | 16.87M |
March 31, 2020 | -4.669M |
December 31, 2019 | -2.75M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-122.50M
Minimum
Sep 2023
16.87M
Maximum
Jun 2020
-62.26M
Average
-75.44M
Median
Dec 2021
Cash from Operations (TTM) Benchmarks
Masimo Corp | 94.10M |
Liquidia Corp | -41.56M |
Vor Biopharma Inc | -100.29M |
CEL-SCI Corp | -23.07M |
AIM ImmunoTech Inc | -21.27M |